Ionic liquid-mediated cellular loading for whole tumor cell vaccines.

Adjuvant-loaded tumor cells (IL-Vax) enhance dendritic cell uptake and activation and provide strong protection against tumor growth in a prophylactic B16F10 melanoma mouse model.

• Why it matters: Whole tumor cell vaccines often fail clinically because immunogenicity is insufficient and adjuvant codelivery is challenging, despite their rich antigen repertoire and patient-specific activity.
• What they did: The study uses a simple single-step ionic liquid-containing cocktail to load immunostimulatory CpG oligodeoxynucleotides into tumor cells undergoing immunogenic cell death, then tests dendritic cell uptake/activation and antitumor efficacy.
• The result: IL-Vax induces potent antitumor immunity, protects against tumor growth in prophylactic B16F10 melanoma mice, and synergizes with PD-1 blockade to slow growth and extend survival in a therapeutic model.